Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIG1 | P18858 | 1/20 | 0.67 |
| ▸ | LMNA | P02545 | 6/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.52 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.52 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 3/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.51 |
| ▸ | TSHR | P16473 | 3/20 | 0.49 |
| ▸ | GAA | P10253 | 2/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9696302 | 0.86 | LIG1 (0.71) | LIG1LMNAKDM4EALDH1A1CYP3A4 | |
| SCHEMBL3942606 | 0.85 | LIG1 (0.54) | LIG1LMNASMN1; SMN2KDM4EALDH1A1 | |
| Acetic Acid SCHEMBL28195889 | 0.85 | LIG1 (0.61) | LIG1LMNASMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL3944765 | 0.85 | LIG1 (0.54) | LIG1LMNASMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL174686 | 0.85 | CYP3A4 (0.74) | LIG1LMNASMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL7934772 | 0.84 | LIG1 (0.59) | LIG1LMNASMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL29519569 | 0.84 | LIG1 (0.69) | LIG1KDM4EALDH1A1CYP3A4ADRB2 | |
| SCHEMBL40310 | 0.84 | LIG1 (0.69) | LIG1KDM4EALDH1A1CYP3A4ADRB2 | |
| SCHEMBL30195826 | 0.83 | LIG1 (0.68) | LIG1LMNASMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL10800031 | 0.83 | LIG1 (0.63) | LIG1KDM4EALDH1A1CYP3A4ADRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 92 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260108497-A1 | OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION | OTSUKA PHARMACEUTICALC., LTD. (JP) | 2026-04-23 | — | — | US | disclosed |
| US-20240148699-A1 | OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2024-05-09 | — | — | US | disclosed |
| EP-4095134-A1 | POLYCYCLIC COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL INDICATIONS | UCL Business Ltd (GB) | 2022-11-30 | — | — | EP | disclosed |
| US-20220265613-A1 | OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2022-08-25 | — | — | US | disclosed |
| US-20200078340-A1 | OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2020-03-12 | — | — | US | disclosed |
| US-20190070151-A1 | OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2019-03-07 | — | — | US | disclosed |
| US-RE46792-E1 | Oxazole compound and pharmaceutical composition | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2018-04-17 | — | — | US | disclosed |
| US-20170216260-A1 | OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2017-08-03 | — | — | US | disclosed |
| EP-2640729-B1 | INHIBITORS OF HIV REPLICATION | VIIV HEALTHCARE UK LTD (GB) | 2016-12-21 | — | — | EP | disclosed |
| EP-2035419-B1 | 5-ARYL-SUBSTITUTED DIHYDROPYRIDOPYRIMIDINES AND DIHYDROPYRIDAZINES AND USE THEREOF AS MINERAL CORTICOID ANTAGONISTS | BAYER IP GMBH (DE) | 2016-06-22 | — | — | EP | disclosed |
| EP-1534698-B1 | FLAVONOID COMPOUNDS AS THERAPEUTIC ANTIOXIDANTS | ROWETT RES INST (GB) | 2007-09-19 | — | — | EP | disclosed |
| WO-2007058338-A2 | OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-05-24 | — | — | WO | disclosed |
| WO-2007025604-A1 | 4-CHROMENONYL-1,4-DIHYDROPYRIDINES AND THEIR USE | BAYER HEALTHCARE AG (DE) | 2007-03-08 | — | — | WO | disclosed |
| WO-2007025604-A1 | 4-CHROMENONYL-1,4-DIHYDROPYRIDINES AND THEIR USE | BAYER HEALTHCARE AG (DE) | 2007-03-08 | — | — | WO | disclosed |
| WO-2007009670-A1 | 4-CHROMENONYL-1,4-DIHYDROPYRIDINECARBONITRILES AND THE USE THEREOF | BAYER HEALTHCARE AG (DE) | 2007-01-25 | — | — | WO | disclosed |
| US-20060137207-A1 | Flavonoid compounds as therapeutic antioxidants | ANTOXIS LIMITED (GB) | 2006-06-29 | — | — | US | disclosed |
| EP-1534698-A1 | FLAVONOID COMPOUNDS AS THERAPEUTIC ANTIOXIDANTS | The Rowett Research Institute (GB) | 2005-06-01 | — | — | EP | disclosed |
| WO-2004007475-A1 | FLAVONOID COMPOUNDS AS THERAPEUTIC ANTIOXIDANTS | ROWETT RESEARCH INSTITUTE (GB) | 2004-01-22 | — | — | WO | disclosed |
| US-6218427-B1 | AS ENDOTHELIN RECEPTOR ANTAGONIST | SHIONOGI & CO., LTD. (JP) | 2001-04-17 | — | — | US | disclosed |
| EP-0924207-A1 | CHROMENE-3-CARBOXYLATE DERIVATIVES | SHIONOGI & CO., LTD. (JP) | 1999-06-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170216260-A1 | OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION | PDE3B, PDE4A, PDE3A | LIG1 1138/4885LMNA 3948/4885SMN1; SMN2 3069/4885 |
| US-20240148699-A1 | OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION | PDE3B, PDE4A, PDE3A | LIG1 1138/4885LMNA 3948/4885SMN1; SMN2 3069/4885 |
| US-20260108497-A1 | OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION | PDE7B, PDE4B, PDE1B | LIG1 2205/4885LMNA 3066/4885SMN1; SMN2 2148/4885 |
| US-20200078340-A1 | OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION | PDE3B, PDE4A, PDE3A | LIG1 1138/4885LMNA 3948/4885SMN1; SMN2 3069/4885 |
| US-20220265613-A1 | OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION | PDE3B, PDE4A, PDE3A | LIG1 1433/4885LMNA 3950/4885SMN1; SMN2 3357/4885 |
| US-20190070151-A1 | OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION | PDE3B, PDE4A, PDE3A | LIG1 1138/4885LMNA 3948/4885SMN1; SMN2 3069/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.